United States Infusion Therapy Market Booming with $73.7B By 2032 Growth Potential | Top 5 Companies - Baxter International Inc., Fresenius Kabi AG, Terumo Corporation, Becton, Dickinson and Company

DataM Intelligence has published a new research report on "Infusion Therapy Market Size 2025". The report explores comprehensive and insightful Information about various key factors like Regional Growth, Segmentation, CAGR, Business Revenue Status of Top Key Players and Drivers. The purpose of this report is to provide a telescopic view of the current market size by value and volume, opportunities, and development status.

Get a Sample PDF Of This Report (Get Higher Priority for Corporate Email ID):- https://datamintelligence.com/download-sample/infusion-therapy-market?kb

Latest Product Launches

Eisai and Biogen have introduced the LEQEMBI IQLIK subcutaneous injection in the US as a new at-home maintenance dosing regimen for Alzheimer's disease, allowing patients to switch from clinic-based intravenous infusions to weekly home injections after an initial phase.

The LEQEMBI Companion Program supports patient education, financial assistance, and therapy adherence, highlighting best practices in next-generation infusion solutions.

Expanded home infusion services are deploying advanced infusion devices and digital platform integrations to improve remote patient delivery and monitoring, reflecting growing product launches in personalized infusion offerings.

Key Players:

B. Braun Melsungen AG, ICU Medical, Inc., Baxter International Inc., Fresenius Kabi AG, Terumo Corporation, Becton, Dickinson and Company, Nipro Corporation, Mindray Medical India Pvt. Ltd., Moog Inc., and Teleflex Incorporated among others.

Latest FDA Approvals

LEQEMBI IQLIK (lecanemab-irmb) received FDA approval in August 2025 as an anti-amyloid therapy for early Alzheimer's disease with the new subcutaneous delivery, marking a shift toward more patient-friendly maintenance dosing.

Cemiplimab-rwlc (Libtayo) was approved by the FDA in October 2025 for adjuvant treatment of cutaneous squamous cell carcinoma via infusion therapy.

Genentech's Tecentriq (atezolizumab) plus lurbinectedin received FDA approval as first-line maintenance infusion for extensive-stage small cell lung cancer in October 2025.

TREMFYA (guselkumab), a biologic for ulcerative colitis, now features fully subcutaneous induction and maintenance dosing for adult patients following recent FDA clearance.

Several new infusion therapies were approved in oncology and autoimmune conditions, bolstering the available pipeline for chronic disease management.

Key Development:

In January 2024, AbbVie launched Produodopa (foslevodopa/foscarbidopa) in the EU, offering the first 24-hour levodopa-based subcutaneous infusion therapy for advanced Parkinson's disease.

In June 2023, Eitan Medical introduced Eitan Insights, a cloud-based infusion management system for home and specialty care. The platform integrates with Eitan's Sapphire and Avoset pumps, featuring the plug-and-play Sapphire Connect accessory and the AvosetGo app for seamless infusion management.

Growth Forecast Projected:

The Global Infusion Therapy Market is anticipated to rise at a considerable rate during the forecast period, between 2025 and 2032. In 2024, the market is growing at a steady rate, and with the rising adoption of strategies by key players, the market is expected to rise over the projected horizon.

Research Process:

Both primary and secondary data sources have been used in the global Infusion Therapy Market research report. During the research process, a wide range of industry-affecting factors are examined, including governmental regulations, market conditions, competitive levels, historical data, market situation, technological advancements, upcoming developments, in related businesses, as well as market volatility, prospects, potential barriers, and challenges.

Buy Now & Unlock 360° Market Intelligence: https://www.datamintelligence.com/buy-now-page?report=infusion-therapy-market

Key Segments:

By Product Type: (Infusion pumps, Intravenous sets, IV Cannulas, Needleless connectors, Vein imaging devices)

By Route of Administration: (Intramuscular, Subcutaneous, Epidural)

By Application: (Antibiotic & viral, Inotropic therapy, Anti-coagulation, Chemotherapy, Nutritional therapy, Blood component, Others)

By End-Users: (Hospitals & Specialty Clinics, Ambulatory Surgery Centers, Homecare Settings)

Regional Analysis for Market:

⇥ North America (U.S., Canada, Mexico)

⇥ Europe (U.K., Italy, Germany, Russia, France, Spain, The Netherlands and Rest of Europe)

⇥ Asia-Pacific (India, Japan, China, South Korea, Australia, Indonesia Rest of Asia Pacific)

⇥ South America (Colombia, Brazil, Argentina, Rest of South America)

⇥ Middle East & Africa (Saudi Arabia, U.A.E., South Africa, Rest of Middle East & Africa)

Investments

Private equity investment activity in infusion therapy remains robust, with platform acquisitions and consolidation targeting alternate site providers and specialty infusion clinics-expected to comprise 70% of the US market within five years.

The home infusion therapy market is attracting investment from device makers, health systems, and digital health platforms aiming to combine remote monitoring and telehealth into chronic care models.

The global IV hydration therapy segment is growing fast, expanding from $2.8 billion in 2024 to a projected $4.9 billion by 2033. Franchise and mobile models are proliferating, supported by consumer demand for wellness-oriented, customized infusion services.

Benefits of the Report:

Chapter 1: Sets the stage by outlining the report's coverage, summarizing key market segments by region, product type, and application. Presents a snapshot of market sizes, growth potential across segments, and anticipated industry evolution both short and long term.

Chapter 2: Highlights pivotal market insights and uncovers the most significant emerging trends driving change within the industry.

Chapter 3: Offers an in-depth look at the competitive landscape among Infusion Therapy producers, including revenue shares, strategic moves, and recent mergers and acquisitions.

Chapter 4: Presents comprehensive profiles of the market's key players, delving into details such as revenue, profit margins, product portfolios, and company milestones.

Chapters 5 & 6: Analyze Infusion Therapy revenue at both regional and country levels, providing quantitative breakdowns of market sizes, growth opportunities, and development prospects worldwide.

Chapter 7: Focuses on different market segments by type, examining their individual sizes and potential, guiding readers toward high-impact, untapped market areas.

Chapter 8: Explores segmentation by application, evaluating industry growth potential in various downstream markets and pinpointing promising sectors for expansion.

Chapter 9: Provides a thorough review of the industry's supply chain mapping out both upstream and downstream activities.

Chapter 10: Concludes with a summary of the report's key findings and highlights the most critical takeaways for industry stakeholders.

Get Customization in the report as per your requirements: https://datamintelligence.com/customize/infusion-therapy-market?kb

FAQ's

Q1: What is the current size of the Infusion Therapy Market?

A: The Infusion Therapy Market stood at US$ 43.5 billion in 2023 and is set to experience remarkable growth, reaching US$ 73.7 billion by 2031

Q2: How fast is the Infusion Therapy Market growing?

A: The Market is on an impressive growth trajectory, expected to expand at a CAGR of 6.8% from 2025 to 2032

Q3: Which regions are dominating the Infusion Therapy Market and which are fastest-growing?

A: North America dominating the Infusion Therapy market.

Latest News

The infusion therapy market is experiencing a strong shift toward alternative sites of care and home-based administration, catalyzed by patient convenience, cost reductions, and regulatory incentives.

Biologics make up 50% of annual FDA infusion therapy approvals, with the regulatory environment favoring innovation and expansion into telehealth-enabled models.

US payors are increasingly incentivizing specialty drug spending in home and alternate care settings, where reimbursement rates are typically 44% lower than hospital-based infusion.

Have any Query? Talk to our Expert @ https://www.datamintelligence.com/enquiry/infusion-therapy-market?kb

Power your decisions with real-time competitor tracking, strategic forecasts, and global investment insights all in one place.

Have a look at our Subscription Dashboard: https://www.youtube.com/watch?v=x5oEiqEqTWg

Contact Us -

Company Name: DataM Intelligence
Contact Person: Sai Kiran
Email: Sai.k@datamintelligence.com
Phone: +1 877 441 4866
Website: https://www.datamintelligence.com

About Us -

DataM Intelligence is a Market Research and Consulting firm that provides end-to-end business solutions to organizations from Research to Consulting. We, at DataM Intelligence, leverage our top trademark trends, insights and developments to emancipate swift and astute solutions to clients like you. We encompass a multitude of syndicate reports and customized reports with a robust methodology.

Our research database features countless statistics and in-depth analyses across a wide range of 6300+ reports in 40+ domains creating business solutions for more than 200+ companies across 50+ countries; catering to the key business research needs that influence the growth trajectory of our vast clientele.

This release was published on openPR.